Congestive Heart Failure (CHF) affects a million people world-wide and every day more patients are diagnosed with this condition, constituting the most frequent cause of hospitalization for the over 65 year old population. The risk of suffering CHF increases in people that are overweight, alcohol and cocaine users, diabetics, and smokers. It does not discriminate between men or women and can affect all ethnic groups.

This condition is the final result of diverse diseases that affect the myocardial function, being the most common vascular disease, diffuse inflammation of the myocardium, greater than 20% myocardial infarction, the arterial hypertension (left ventricle) or pulmonary (right ventricle), expanded myocardiopathy, congenital cardiac diseases, cardiac tumors or diseases of the coronary arteries.

The compensating mechanisms which are triggered with the purpose of normalizing the ventricular function produce clinical manifestations, such as: tachycardia, growth of the heart (cardiomegaly), pulmonary congestion or edema, easy fatigue, sleeping disorders, respiratory difficulty, cough, reduction in urine production, or growth of the liver (hepatomegaly).  The patient could have walking difficulties as well as problems carrying loads and climbing stairs. Patients experience breathing difficulties, since the organism does not have enough oxygen to function normally.

CHF treatment requires continuous monitoring on behalf of the doctor, which means identifying -and treating- any underlying disorders undertaking a periodic efficiency evaluation of the heart's blood volumetric pumping capacity through an echocardiogram. 

Complementing the conventional treatment with a Systemic Medicine protocol, the patients' perspective of coming to terms with CHF improve considerably, many have been able to return to their normal activities, sometimes with minimum limitations, obtaining therefore a more satisfactory quality of life.

This has been corroborated with results of a retrospective, multicenter clinical study of 80 CHF patients degrees III and IV, which received complementary treatment with Systemic Medicine.

Improvement in respiratory difficulty was obtained in 93% of the patients; reduction of hepatomegaly was 83%; diminution of edema: 93% of patients with peripheral edema; and in 100% of those which presented/displayed generalized edema; attenuation or disappearance of cough and tachycardia in 97% of patients; 94% of the patients recovered appetite; 95% of the patients improved urinary symptoms; and 94 % of patients improved the fatigue and weakness.

In general the clinical evolution was beneficial in 93% of the cases, as well as quality of life. Tolerance to treatment was excellent, no indirect effects were observed.